Aquestive Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information Item 9C
Our Chief Operating Officer Cassie Jung adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the "Jung Plan") on December 10, 2024. The Jung Plan commences on March 11, 2025 and ends on December 31, 2025. The maximum number of shares to be sold under the Jung Plan is 108,656 shares; the actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Jung Plan.
Our Chief Medical Officer Carl Kraus adopted a written sales plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (the "Kraus Plan") on December 12, 2024. The Kraus Plan commences on March 17, 2025 and ends on February 27, 2026. The maximum number of shares to be sold under the Kraus Plan is 75,000. The actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the Kraus Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.